Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.
about
Cancer stem cell metabolismInfectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective TherapyClinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)The Role of Infectious Agents in the Etiology of Ocular Adnexal NeoplasiaOcular adnexal lymphoma and infectious agentsThe role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.Genome-wide DNA methylation profiles according to Chlamydophila psittaci infection and the response to doxycycline treatment in ocular adnexal lymphoma.Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients.Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease.Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution.Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy.Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa.High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.Chlamydiae and Mycoplasma infections in pulmonary MALT lymphomaMolecular modeling-based inclusion mechanism and stability studies of doxycycline and hydroxypropyl-β-cyclodextrin complex for ophthalmic delivery.A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphomaOcular adnexal non-Hodgkin's lymphoma: a review of epidemiology and risk factorsDescriptive epidemiology of ophthalmic and ocular adnexal non-Hodgkin's lymphoma.A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.Ocular adnexal mucosa-associated lymphoid tissue lymphoma in Northern China: high frequency of numerical chromosomal changes and no evidence of an association with Chlamydia psittaci.Treatment options for ocular adnexal lymphoma (OAL).[Chlamydial diseases of the eye. A short overview]Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type.Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa.Mitochondrial ribosomes in cancer.Associations of Autoimmunity, Immunodeficiency, Lymphomagenesis, and Gut Microbiota in Mice with Knockins for a Pathogenic Autoantibody.Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma.Update on conjunctival pathology.Unconventional therapies in ocular adnexal lymphomas.Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose.Prevalence of chlamydial infection in a series of 108 primary cutaneous lymphomas.The 2017 Doyne Lecture: the orbit as a window to systemic disease.Antibiotic use and risk of non-Hodgkin lymphomas.Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma.Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.
P2860
Q26746123-65F2DA23-1594-433B-A620-A7C102CCAE89Q26770344-4BA34988-5ECA-48F7-8B24-26A010374BD4Q26771654-96092823-B140-4642-8326-152B45CC7391Q27486618-F26BDB26-A384-4796-8BB1-1A707456E029Q27488262-BC33527A-3575-4DF5-B1F9-4C433F70208CQ30299948-D391615A-2313-4875-8747-1FE21D16F874Q33926617-63CF7B9E-FCFD-4469-9D73-0130F1F5894DQ33982223-C26D9C65-B46C-4F40-9D27-FFA3103634A4Q35741510-07A02916-15FC-43D6-8AFD-D6225E36C075Q35968270-1E25F87C-3956-437B-8525-90944E3C8E34Q35987267-8C7E1081-7A21-435D-8920-E0183B8FBD5CQ36074644-B274F750-D0D1-4487-967B-B3407CA50420Q36544355-78FDFA8A-C7A7-419B-9045-884F6584B5AEQ36611345-9367CF08-5EF3-49DB-B943-3208A6374E3DQ36636481-5F9458F8-EECC-4D42-B96A-7CE221643A31Q37038505-D5943F66-597A-4328-95D6-5F3F789705B1Q37111613-BF77AA98-45DD-4AA0-AB43-F4116FDBC846Q37396033-4F3097DA-1A43-433C-B9E0-FD67A0964E50Q37499970-33537264-9AAA-4785-AF4C-25F84FDF8A43Q37553676-080B29B8-44D6-49D4-A3BB-DBEB984AE674Q37852439-74498963-2EAB-4BA0-A294-9956BFBAB75AQ37853817-10957686-6075-4B73-B154-F0E27928C339Q37860577-A58C5422-E0DA-4837-8534-40E46EE92C5EQ37944372-2899A12A-7D97-4821-9035-E924136E74D3Q38544142-A90F8C35-F254-434B-91A0-D89BDA579A6CQ38842920-9D463DCE-501A-4726-83D9-4C9F7FD352ACQ39264654-16BEAB2A-9A11-4BEC-8F45-33C337A2450DQ40114844-49780546-C318-4B33-BB68-77D14B0D5379Q41691477-F8A4D7AA-CB8D-43E0-9A59-E4FEE579575AQ42367341-8C23023B-EF09-44FC-BA71-CDBB4893CD80Q42909161-583B0F61-B498-4510-B9B5-009A48AD7A7AQ43242535-A20A7946-7D98-4011-9DFD-158AA707E18EQ43411762-02637654-6EFD-4B83-8578-6874C15C2FA9Q44059279-20445412-5B0E-460A-8196-89A6A2C16A83Q44956299-3017A252-9492-490D-8360-C67D3A24190BQ47119181-A6D5328D-3AE8-4D9E-A605-B75EAF7F1101Q51605001-664E214D-86F4-47BE-A8C5-4422A99B439EQ53049966-8913CE92-5C7F-470D-9F98-3C1C33D264B6Q55254924-0323C519-2C25-43DB-80F1-8F3880FA09D4
P2860
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bacteria-eradicating therapy w ...... multicenter prospective trial.
@en
Bacteria-eradicating therapy w ...... multicenter prospective trial.
@nl
type
label
Bacteria-eradicating therapy w ...... multicenter prospective trial.
@en
Bacteria-eradicating therapy w ...... multicenter prospective trial.
@nl
prefLabel
Bacteria-eradicating therapy w ...... multicenter prospective trial.
@en
Bacteria-eradicating therapy w ...... multicenter prospective trial.
@nl
P2093
P2860
P50
P356
P1476
Bacteria-eradicating therapy w ...... multicenter prospective trial.
@en
P2093
Andrés J M Ferreri
Angelo Palmas
Antonio Giordano Resti
Carlo De Conciliis
Elisa Pasini
Federico Sacchetti
Francesco Zallio
Giuliana Muti
Giuseppina P Dognini
Judit Demeter
P2860
P304
P356
10.1093/JNCI/DJJ373
P407
P577
2006-10-01T00:00:00Z